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Abstract
The prevalence of reported diabetes was 2.9 times higher in overweight than in
non-overweight persons as proved by the National Health and Nutrition Examination
Survey (NHANES III) data. The majority of individuals with type 2 diabetes develop
insulin resistance associated with overall obesity. Several lines of evidence indicate that
many of the metabolic derangements associated with obesity and type 2 diabetes
originate from dysregulation of lipid metabolism.
TALLYHO/Jng (TH) mice are a newly established inbred polygenic model for
obesity and type 2 diabetes. These mice are characterized by insulin resistance,
hyperinsulinemia, diabetes (males) obesity, and dyslipidemia including
hypertriglyceridemia (HTG). TH male mice rapidly develop HTG at a very young age
before the onset of overt diabetes, and this HTG is accompanied by hyperinsulinemia,
and preceded glucose intolerance.
The goal of this study is to characterize the lipodysregulation in TH mouse. In
order to achieve this goal, we measured tissue triglyceride content in non-adipose tissue,
and hepatic fatty acid β-oxidation rates in diabetic TH mice. TH male mice exhibit
significantly elevated TG content and lipid accumulation in skeletal muscle, liver, and
kidney. Attenuated hepatic fatty acid oxidation was also featured in male diabetic TH
mice although it was not statistically significant. It is likely speculated that impaired
fatty acid oxidation in liver may be in part responsible for the HTG, elevating TG content
in peripheral tissue including the skeletal muscle, which may be attributable to the
impaired insulin sensitivity and diabetes in male TH mice. Elucidating the mechanism of
lipodysregulation in diabetic model of TH mice will provide insights into the causes and
mechanisms underlying the metabolic complications of insulin resistance and diabetes
and ultimately improved therapeutic strategies for prevention and treatment of type 2
diabetes.
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Chapter І: Introduction
The World Health Organization referred to the increased prevalence of obesity
and diabetes as the 21st century epidemic (1). Obesity is the most common metabolic
disease worldwide (2). More over, its incidence and prevalence are rising rapidly (3).
The global incidence of type 2 diabetes mellitus (T2DM) is projected to be nearly 300
million people by the year 2025, and many of those affected will be young adults.
Successful strategies to halt this epidemic will require a better mechanistic understanding
of how the disease arises (4). Nearly all individuals with T2DM are insulin resistant, and
the majority of them are obese (5). An increase in overall fatness, specifically of visceral
as well as ectopic fat depot, is associated with insulin resistance (6). Over the last
decade, major advances have been made to understand the pathophsiology and molecular
biology of T2DM (7,8). T2DM is a bipolar disease where both insulin secretion and
insulin action are defective. This complex interaction leads to a progressive increase of
plasma glucose levels (9). It is also well established that the development of T2DM
results from an interaction between subjects’ genetic makeup and their environment, and
that with the increasing prevalence of obesity, the prevalence T2DM is reaching epidemic
proportions (10). Various organs play a crucial role in the pathophysiology of T2DM.
Disruption of the cross talks between endocrine pancreas, liver, skeletal muscle, adipose
tissue, and presumably gut and central nervous system may lead to impairment of
homeostasis and T2DM (11,12).
Although most patients with T2DM are overweight or obese (10), the role of fat
was initially neglected in the pathophysiology of the disease (11). The role of fat,
1

especially the interaction of non-esterified fatty acids with glucose metabolism started to
be highlighted almost a decade ago (12). The crucial impact of fat distribution, especially
the negative influence of intra-abdominal or visceral fat depot is now better recognized
(13). The concept of lipotoxicity has developed recently, where the deleterious role of
ectopic triglyceride storage in the development of defective insulin action and insulin
secretion has been emphasized (14). In addition, adipose tissue can secrete adipokines
that may affect glucose metabolism and insulin sensitivity, such as leptin, tumor necrosis
factor (TNF)-α, resistin, and adiponectin (15).
The ectopic fat storage hypothesis states that if fat mass can not expand through
proliferation and differentiation of adipocytes in times of positive energy balance, then
adipocyte hypertrophy results, and the excess dietary fat will be shunted to the liver,
skeletal muscles, and pancreatic β-cells. If fat oxidation capacity cannot be increased to
compensate for the increased influx of lipids within these tissues, then intracellular
accumulation of lipids occurs (16).
In obesity and T2DM, the lipid content within and around muscle fibers is
increased. Changes in muscle in fuel partitioning of lipid between oxidation and storage
of fat calories, contributes to the accumulation of intramyocellulr triglyceride (IMTG)
and to the pathogenesis of both obesity and T2DM (17).
The prevalence of hepatosteatosis (increased lipid accumulation in the liver) is
increased in T2DM. A recent clinical investigation on patients with T2DM treated with
insulin, indicated that hepatic triglyceride content is a strong determinant of hepatic
insulin resistance (5).
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Various lipid disorders appear to be related to both diabetes mellitus and to
insulin resistance.

A high triglyceride and a low high-density lipoprotein (HDL)

cholesterol level appear usually to coincide in individuals with diabetes and insulin
resistance. These disorders are at least twice as prevalent as among other individuals
(18).
The medical and socioeconomic burden of T2DM is caused by the associated
complications (19,20), which impose enormous strains on health-care systems (Figure1).
The incremental costs of patients with T2DM arise at least 8 years earlier before the
diagnosis of the disease is established (21). The devastating complications of diabetes
mellitus are mostly macrovascular and microvascular diseases as a consequence of
accelerated atherogenesis. Cardiovascular morbidity in patients with T2DM is two to
four times greater than that of non-diabetic population (22).
Animal models have been used as an adjunct to human studies to minimize
difficulties encountered while studying obesity and T2DM in humans, largely by the
capability of genetic and environmental controls (23-27).

In addition, rodents and

humans share biological and physiological characteristics, so it is possible to apply
information discovered in rodents to humans (28,29).
TALLYHO/Jng (TH) mice are a newly established inbred polygenic model for
obesity and type 2 diabetes.

These mice are characterized by insulin resistance,

hyperinsulinemia,

(males)

diabetes

obesity,

and

dyslipidemia

including

hypertriglyceridemia (HTG). TH male mice rapidly develop HTG at a very young age
before the onset of overt diabetes, and this HTG is accompanied by hyperinsulinemia,
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Figure 1: Economic impact of diabetes:
The cost of diabetes affects health services, national productivity as well as individuals
and families. Hospital in- patient costs for treatment of complications are the largest
single contributor to direct health care costs.
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and preceded glucose intolerance.
The goal of this study is to characterize the lipodysregulation in TH mouse. Studying the
pathophysiological mechanisms of lipodysregulation in TH mice will lead to better
understanding of the disease process and will provide a framework that explains the links
between lipid and glucose metabolism. It may as well lead to the development of new
pharmacological strategies to treat T2DM

5

Chapter Ⅱ: Literature Review
1) Obesity and type 2 diabetes
The prevalence of obesity [defined as a body mass index (BMI) above 30] is
increasing rapidly in many countries, almost reaching epidemic proportions in some areas
(30). The high prevalence of obesity has led to an increase in the co-morbid conditions
of obesity especially type 2 diabetes (also known as non insulin dependent diabetes
mellitus), hypertension, cardiovascular disease, and certain cancers (31,32). Type 2
diabetes is the most common metabolic disease in the world. In the United States, it is the
leading cause of blindness, end-stage renal disease, and limb amputation, with associated
health care costs estimated to exceed $130 billion per year (33).
Type 2 diabetes is a heterogeneous syndrome characterized by abnormalities of
carbohydrate and fat metabolism. The causes of type 2 diabetes are multifactorial and
include both genetic and environmental elements that affect beta cell function and various
tissue (muscle, liver, adipose tissue, and pancreas) insulin sensitivity (34).
Positive energy balance in our obesigenic environment (where there is increased
availability and over-consumption of foods high in energy, and a concomitant decline in
activity dependent energy expenditure) leads to excess lipid storage in liver (35) and
skeletal muscles (36,37) followed by insulin resistance, glucose intolerance and diabetes.
When energy intake is greater than energy expenditure, excess dietary fat will lead to
adipocyte hypertrophy, and fat storage in ectopic sites such as liver, skeletal muscle, and
the pancreatic beta cells. Ectopic lipid decreases insulin action leading to
hyperinsulinemia and predisposing to type 2 diabetes (38). It has been observed by using
6

magnetic imaging techniques such as computed tomography and magnetic resonance
imaging that visceral fat accumulation is specifically associated with metabolic alteration
of obesity, both in men and women (39-42). It was also noticed that obese women with
greater proportion of upper body fat are more likely to have dyslipidemia,
hyperinsulinemia, and glucose intolerance than obese women with a greater proportion of
lower body fat (43).
2) Regulation of blood glucose level
According to the American Diabetes Association (175), criteria for the diagnosis
of diabetes are shown in Table 1.

Table 1: Criteria for the diagnosis of diabetes.
Normoglycemia

IFG or IGT

Diabetes

FPG <100 mg/dl

FPG ≥ 100 and

FPG ≥126 mg/dl

< 126 mg/dl (IFG)
2-h PG <140 mg/dl

2-h PG ≥140 and

2-h PG ≥ 200 mg/dl

< 200 mg/dl (IGT)

Symptoms of diabetes and
causal PG ≥ 200 mg/dl

FPG; Fasting Plasma glucose, IFG; Impaired fasting glucose, IGT; Impaired glucose tolerance; 2-h PG two
hours postload glucose: This test requires use of a glucose load containing the equivalent of 75 g anhydrous
glucose dissolved in water.
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Maintenance of normal blood glucose levels depends on a complex interaction between
the insulin responsiveness of skeletal muscle and liver and glucose stimulated insulin
secretion by pancreatic β-cells.

Defects in the former are responsible for insulin

resistance, and defects in the latter are responsible for progression to hyperglycemia (44).
Insulin signaling:
Insulin is the most potent anabolic hormone known. It promotes the synthesis of
carbohydrates, fats, and lipids, and inhibits their degradation and release back into the
Circulation (45). The insulin receptor is a tyrosine kinase that undergoes
autophosphorylation upon insulin binding, and catalyzes the phosphorylation of several
intracellular substrates including the insulin receptor substrate (IRS1 - IRS4) proteins,
GAB-1, Sch (46), APS, P60 DOK, SIRPS, and c-Cb1 (47-52). Upon tyrosine
phosphorylation, each of these subunits interacts with a series of signaling proteins
containing Src-homology 2 (SH2) domains leading to initiation of different signaling
pathways. Each of these pathways plays a separate role in the different cellular effects of
insulin (Figure2). Initiation of these signaling pathways stimulates the trafficking of Glut
4 vesicles, their docking, and their fusion with the plasma membrane, and enhance
glucose uptake by the cells (53).
3) Insulin resistance
Insulin resistance is a state of reduced responsiveness to normal circulating levels
of insulin (54). It is an early feature of type 2 diabetes as indicated by the following:
First, virtually all patients with type 2 diabetes are insulin resistant, and prospective
studies have shown that this insulin resistant state develops 1-2 decades before the onset
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Glucose
Caveolin

Flotillin

CAP
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GTP GDP
Cb1

Y-P

CRK

PDK1

TC10
C3G

PKC
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PIP-3

Y-P
PI3-K

IRS

GLUT4

Figure 2: Insulin signaling pathway: A model for diverse signaling pathways in insulin
action. Two signaling pathways are required for the translocation of the glucose
transporter Glut 4 by insulin in fat and muscle cells. Tyrosine phosphorylation (Y-P) of
the insulin receptor substrate (IRS) proteins after insulin stimulation leads to an
interaction with and subsequent activation of the Src-homology 2 (SH2)-domaincontaining protein phosphatidylinositol 3-kinase (PI3-K), producing the
polyphosphoinositide phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which in turn
interacts with and localizes protein kinases such as phosphoinositide-dependent kinase 1
(PDK1). These kinases then initiate a cascade of phosphorylation events, resulting in the
activation of Akt and/or atypical protein kinase C (PKC). A separate pool of the insulin
receptor can also phosphorylate the substrates Cbl and APS. Cbl interacts with Cblassociated protein (CAP), which can bind to the lipid raft protein flotillin. This
interaction recruits phosphorylated Cbl into the lipid raft, resulting in the recruitment of
the SH2/SH3 adaptor protein CrkII through an interaction of the SH2 domain of CrkII
with phosphorylated Cbl. CrkII binds constitutively to the GDP–GTP factor C3G, which
can catalyze the exchange of GTP for GDP on the lipid-raft-associated protein TC10.
Upon activation, TC10 interacts with one or more effectors to initiate a separate signaling
pathway that, along with the PIP3-dependent protein kinases, can stimulate the
trafficking of Glut4 vesicles, their docking and their fusion with the plasma membrane
(53).
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of the disease (55-57). Second, insulin resistance in the offspring of parents with type 2
diabetes is the best predictor for later development of the disease (58).

Lastly,

perturbations that reduce insulin resistance prevent the development of diabetes (59).
Insulin resistance is said to be present when the biological effects of insulin are
less than expected for both glucose disposal in skeletal muscle and suppression of
endogenous glucose production primarily in the liver (60). In the fasting state, however,
muscle accounts for only a small proportion of glucose disposal (less than 20%) whereas
endogenous glucose production is responsible for all the glucose entering the plasma.
Endogenous glucose production is increased in patients with type 2 diabetes or impaired
fasting glucose (61,62).

Because this increase occurs in the presence of

hyperinsulinemia, at least in the early and intermediate disease stages, hepatic insulin
resistance is the driving force of hyperglycaemia of type 2 diabetes (Figure 3).
Skeletal muscle and liver are the two key insulin-responsive organs responsible
for maintaining normal glucose homeostasis, and their transition to an insulin resistant
state accounts for most of the alterations in glucose metabolism seen in patients with type
2 diabetes (44).
Pathophysiology of hyperglycemia
In order to understand the cellular and molecular mechanisms responsible for
development of type 2 diabetes, it is necessary to determine how glycemia is controlled.
Insulin is the key hormone for regulation of blood glucose and, generally, normoglycemia
is maintained by the balanced interplay between insulin action and insulin secretion.
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Diabetes genes
Adipokines
Inflammation
Hyperglycemia
Free fatty acids
Other factors

Pancreas

(1)

Beta cell
dysfunction
Insulin

Insulin resistance

Glucose (2)
production

(4)

(3)

Lipolysis

Glucose uptake

Liver
Muscle
Fat

(5)

Blood Glucose
(6)

Fatty acids

Figure 3: Pathophysiology of hyperglycemia and increased fatty acids in type 2
diabetes: Insulin secretion from the pancreas (1) normally reduces glucose output by the
liver (2), enhances glucose uptake by skeletal muscle (3), and suppresses fatty acid
release from fat tissue (4). The various factors shown that contribute to the pathogenesis
of type 2 diabetes affect both insulin secretion and insulin action. Decreased insulin
secretion will reduce insulin signaling in its target tissues. Insulin resistance pathways
affect the action of insulin in each of the major target tissues, leading to increased
circulating fatty acids and the hyperglycaemia of diabetes. In turn, the raised
concentrations of glucose and fatty acids in the bloodstream will feed back to worsen
both insulin secretion and insulin resistance. (Adapted from (22)).
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Importantly, the normal pancreatic β-cell can adapt to changes in insulin action i.e., a
decrease in insulin action is accompanied by up-regulation of insulin secretion (and vice
versa) (63).
Deviation from this balanced mechanism, such as in the patients with impaired
glucose tolerance and type 2 diabetes, occurs when β-cell function is inadequately low for
a specific degree of insulin sensitivity. Thus, β-cell dysfunction is a critical component in
the pathogenesis of type 2 diabetes. This concept has been verified in cross- sectional as
well as longitudinal studies in Pima Indians progressing from normal to impaired glucose
tolerance to type 2 diabetes (64), when insulin action decreases (as with increasing
obesity) the system usually compensates by increasing β-cell function. However, at the
Same time, concentrations of blood glucose at fasting and 2 hours after glucose load will
increase mildly (64). This increase may first be small, but over time becomes damaging
because of glucose toxicity, and may itself cause β-cell dysfunction. Thus, even with
(theoretically) unlimited β-cell reserve, insulin resistance paves the way for
hyperglycemia and type 2 diabetes (22).
4) Fatty acid metabolism
When fuel molecules are available in amounts greater than energy needs, fatty
acids are synthesized, esterified to glycerol and stored as triglycerides (TG) in adipose
tissue. On the other hand, when there is an energy need, stored fatty acids must be
released from triglycerol and transported to the mitochondria of peripheral tissues, where
they are degraded. Catabolism of fatty acids is brought about by β-oxidation, a four-step
process yielding acetyl CoA, which feeds into aerobic metabolism at the citric acid cycle
(Figure 4).
12

Glycogen
Glucose 1 phosphate
Glucose

Glucose 6 phosphate
Pyruvate
Beta-oxidation of
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Acetyl CoA
Energy
metabolism

Storage
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Fatty acids
ATP production by
oxidative phosphorylation

Triglycerols

Figure 4: The linkage between carbohydrate and fatty acid
metabolism. Actyl CoA is produced from β-oxidation of dietary
fatty acids and from glycolysis plus pyruvate oxidation. Excess
acetyl CoA may be used to make Fatty acids stored in triglycerols.
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β-oxidation begins in the mitochondrial matrix after the entry of fatty acids. Carnitine
acyl transferase II catalyses the final steps in the transport by linking the fatty acids to
mitochondrial CoASH. β-oxidation of fatty acyl CoA takes place by recurring series of
four steps:
1)Oxidation of the carbon-carbon single bond by FAD to form carbon-carbon double
bond.
2) Addition of H2O to the double bond, with the formation of a hydroxyl group on
one carbon.
3) Oxidation of the hydroxyl group by NAD+ to produce a ketogroup
4) Carbon-carbon bond cleavage, releasing acetyl CoA.
Significance of β-oxidation
β-oxidation products are of a great metabolic importance. The net reaction for betaoxidation of palmitic acid is:
Palmitic acid + ATP + 7 FAD + 7 NAD + 8 CoASH + 8 H2O→ 8 acetyl SCoA + AMP+
2 Pi + 7 FADH2 + 7 NADH +7 H+
The acetyl CoA is ready for further oxidation by the citric acid cycle. The
enzymes needed for citric acid cycle are present in the mitochondrial matrix, the same
location as the enzymes for β-oxidation.
The complete degradation of palmitoyl CoA requires seven turns of β-oxidation,
and each round requires the entry of FAD, NAD, H2O, and CoASH. The complete
oxidation of palmitate to CO2 and H2O yields 129 ATP
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5) Dyslipidemia and insulin resistance
Research has established healthy ranges for lipoprotein profiles. According to
American Heart Association (65), table (2) illustrates the initial classification for the lipid
profile.
Patients with DM, particularly those with type 2 diabetes, have characteristic
abnormalities of plasma lipids and lipoprotein concentrations that almost certainly play a
significant role in the increased risk for coronary artery disease (CAD).

This

dyslipidemia is characterized by higher plasma (TG) levels, both in fasting and the
postprandial state, reduced levels of high density lipoprotein (HDL) cholesterol, and
abnormal low density lipoprotein (LDL) particles. Plasma free fatty acid concentrations
are increased in many insulin resistant states, including obesity and type 2 diabetes
mellitus (66).
More recently, the concept of lipotoxicity involving the β cell has been put
forward. Generally, in both non-diabetic and diabetic obese patients, non estrified fatty
acids (NEFA) concentrations are raised as a result of enhanced adipocyte lipolysis. Fatty
acids lead to enhanced insulin secretion in acute studies, but after 24 hours they actually
inhibit insulin secretion (22).
Free fatty acids are insulinotropic (67), and this action is an important mechanism
to protect against hypoinsulinemia during fasting, when glucose; the primary stimulant
for pancreatic insulin secretion is not available. The availability of FFA, derived from

15

Table 2: Blood total cholesterol, HDL cholesterol, LDL cholesterol, and TG
level classification (from American Heart Association) (65).

Total cholesterol
< 200 mg/dl
200 to 239 mg/dl
240 mg/dl and above
HDL cholesterol
< 40mg/dl (for men)
< 50 mg/dl (for women)
60 mg/dl and above
LDL cholesterol
< 100 mg/dl
100-129 mg/dl
130-159 mg/dl
160-189 mg/dl
190 mg/dl and above
Triglyceride
<150 mg/dl
150-199 mg/dl
200-499 mg/dl
500 mg/dl and above

Category
Desirable level
Borderline high
High. More than twice the risk of
Coronary heart disease
Low HDL. A major risk for heart disease.
High HDL. Considered protective against heart disease
Optimal
Near or above optimal
Borderline high
High
Very high
Normal
Borderline high
High
Very high

HDL: High density lipoprotein, LDL: Low density lipoprotein
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adipose tissue, ensures the secretion of a minimal level of insulin that is essential for
prevention of unrestrained free fatty acid output from adipose tissue (68-70). Excess
inflow of FFA and accumulation of TG in β-cells have a negative effect on β-cell
function.

The increased secretion pressure results in beta cell deterioration up to

apoptosis (71).

Understanding the pathophysiology underlying this dyslipidemia is

crucial to optimizing therapy in patients with diabetes (72).
Mechanism of fatty acid induced insulin resistance
In 1963, the Randle hypothesis stated that fatty acids caused insulin resistance by
a substrate competition mechanism (73,74).

According to this hypothesis, increased

fatty acid oxidation in muscles will lead to high production of intracellular acetyl CoA
and citrate, which in turn inhibit 2 enzymes involved in glucose utilization (44). These
enzymes are pyruvate dehydrogenase and phosphofructokinase (Figure 5). This in turn
leads to increased intracellular glucose and glucose 6 phosphate concentration, which
inhibits hexokinase and results in reduced insulin stimulated glucose uptake and
oxidation (44).
Recent studies indicated that this mechanism for fatty acid induced insulin
resistance does not apply in human skeletal muscles (75). These studies proposed that
fatty acids cause insulin resistance by inhibiting insulin stimulated glucose transport
activity through accumulation of intracellular fatty acyl CoA, and diacyl glycerol, and
possibly ceramides. This accumulation leads to activation of critical signal transduction
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Free fatty acids (1)

Plasma glucose
Glut 4
(9)
Glucose
(8)
HK ---

(3)
NADH
NAD+

Glucose 6 phosphate (7)
(2)

Acetyl Co A
Co A
(5)
Citrate

PFK

PDH
---(4)

Pyruvate

--(6)

Figure 5: Mechanism of free fatty acid induced insulin resistance in skeletal
muscle. The Randle cycle. The increased FFA concentration (1) results in an elevation
of the intra-mitochondrial Acetyl CoA/Co A (2) and NADH/NAD+ (3) ratio, with
subsequent inactivation of PDH (4).This in turn causes citrate concentration to increase
(5), leading to inhibition of PFK (6). Subsequent increase in intracellular G6P
concentration (7) will inhibit HK activity (8), which results in an increase in intracellular
glucose concentratio(9), and decrease in muscle glucose uptake.Glut 4, glucose
transporter 4; HK, hexokinase; G6p, glucose 6 phosphate; PFK, phosphofructokinase;
PDH, pyruvate dehydrogenase;
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pathways that ultimately suppress insulin signaling (76) (Figure 6).

The proposed

mechanism is as follows:
Fatty acid metabolites (long chain acyl CoA and diacyl glycerol) accumulate inside the
cells because of increased fatty acid delivery or decreased mitochondrial β- oxidation,
trigger serine/threonine kinase cascade (possibly involving new protein kinase C). This
eventually induces serine/threonine phosphorylation of critical IRS-1 sites, therefore
inhibiting IRS-1 binding and activation of PI3-kinase, resulting in reduced insulin
stimulated glucose transport (77).
In the liver, the associated activation of pyruvate carboxylase by the high
availability of acetyl CoA derived from fatty acid oxidation results in stimulation of
gluconeogenesis (78).
6) Lipid lowering medications
Although behavioral interventions such as diet exercise, and smoking cessation
can help to improve dyslipidemia, most patients need pharmacological therapy to reach
treatment goals(79). There are several classes of medications used in the management of
dyslipidemia associated with insulin resistance and type 2 diabetes including statins,
fibrates, niacin, and thiazolidinediones (80).
Statins (HMG-CoA reductase inhibitors)
Statins lower LDL levels and can also to varying degrees lower plasma TG levels
and raise HDL cholesterol. Statin mediates its action on plasma lipoproteins through
increasing LDL receptor activity and reducing hepatic lipoprotein secretion (81).
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Figure 6: Proposed mechanism of fatty acid induced insulin resistance. Free fatty
acid metabolites such as DAG, fatty acyl CoA, and ceramides activate a serine/threonine
kinase cascade leading to phosphorylation of serine threonine sites on IRS-1 which in
turn reduces the ability of IRS-1 to activate PI3-K with consequent decrease in glucose
transport activity. LcCoA: long chain acyl CoA, DAG: Diacyl glycerol, S: Insulin
receptor subunit, PI3- kinase: phosphatidyl inositol 3 kinase.
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Fibrates (Peroxisome proliferator-activated receptor-α agonists)
Fibrates reduce plasma levels of TG rich lipoproteins. This effect is mediated by
transcriptional regulation of genes that promote clearance of TG rich lipoproteins i.e.: It
increases lipoprotein lipase and its activator apolipoprotein (apoCII), and inhibits
(apoCIII), a protein that reduces lipolysis of TG rich lipoproteins and clearance of their
remenants (82). Fibrates also raise HDL apparently through increasing production of
HDL apoproteins and reducing transfer of cholesterol ester from HDL to VLDL (83,84).
The effects of fibrates on LDL cholesterol are variable. A number of studies have shown
that fibrates can reduce the levels of small dense LDL and reverse the small LDL
phenotype (85-87).

This effect might be due to the beneficial effects on TG rich

lipoprotein metabolism as well as the reduced activity of cholesterol ester transfer Fibrate
treatment can be effective in normalizing the atherogenic dyslipidemic picture in patients
with type 2 diabetes (88,89).
Niacin (nicotinic acid)
Niacin significantly reduces TG levels, increases HDL levels, and increased LDL
particle size, and therefore improves the atherogenic lipoprotein profile.

Niacin

suppresses the hepatic production of VLDL, and reduces fatty acid release from adipose
tissue. It has been found that the HDL rising effect of niacin is potentiated by an increase
in the effective half-life of HDL due to reduced uptake by the receptors responsible for
intrahepatic degradation of HDL (90).
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TZDs (peroxisome proliferator-activated receptor-γ agonists)
TZDS have an insulin-sensitizing effect that lowers glucose levels in patients with
type 2 diabetes. It was observed that TZDs exert beneficial effect on lipoproteins and
may improve some aspects of dyslipidemia associated with type 2 diabetes (91). Total
cholesterol and LDL levels tend to increase with TZDs therapy, and there is a consistent
increase in HDL cholesterol. TG levels decrease with poiglitazone therapy and also are
reduced with rosiglitazone in patients with elevated baseline TG levels (92-94).
7) Ectopic fat and insulin resistance
Although standard definitions of insulin resistance still define it in terms of the
effects of insulin on glucose metabolism, the last decade has seen a shift from the
traditional “glucocentric” view of diabetes to an increasingly acknowledged
“lipocentric”view point (77). This hypothesis holds that abnormalities in fatty acid
metabolism may result in inappropriate accumulation of lipids in muscle, liver, and βcells (68).

It is further proposed that ectopic fat accumulation is involved in the

development of insulin resistance in muscle and liver as well as impairing β- cell function
(so called lipotoxicity) (95). Lipid accumulation within myocytes and hepatocytes is
strongly associated with insulin resistance in diabetics (66), non diabetic relatives of
patients with type 2 diabetes (a cohort at high risk of developing diabetes)(96),
individuals with impaired glucose tolerance, and obese subjects (97).
In obesity, fat cells, which are already overloaded with TG, fail in their normal
role of protecting other tissues from dietary fatty acid influx. The increased flux of FFA
and TG in the circulation has an adverse effect on insulin sensitivity, as well as a longer
term effect; that is accumulation of TG in glucose-metabolizing tissues such as skeletal
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muscle, liver, and pancreatic β-cells.

This accumulation of TG in β-cells leads to

impairment of insulin secretion in response to glucose. This view has been consistent in
a large number of both human and animal studies. Thus, the adipose tissue is now
recognized as being a highly active, closely regulated metabolic tissue that performs the
vital role of buffering FFAs flux into the circulation against the variable input of dietary
fat from hour to hour. When this buffering capacity is overwhelmed by consistent intake
of fat above the rate of oxidation, the dietary fat must go elsewhere, and its deposition in
non-adipose tissue leads eventually to insulin resistance and beta-cell dysfunction (78).
Reduction of ectopic fat lipid accumulation in the liver, muscle, and beta cells may prove
to be an additional goal for future pharmacological interventions (98).
Muscle triglyceride and insulin resistance
TG content in skeletal muscle is increased in cases of obesity and type 2 diabetes,
and is considered to be a strong predictor of insulin resistance (99,100). In a cross
sectional study of healthy, young, lean offspring of type 2diabetic patients, there was an
inverse relationship between intramyocellular lipid (IMCL) content as measured by H
MRS and insulin sensitivity, consistent with the hypothesis that altered fatty acid
metabolism contributes to insulin resistance in patients with type 2 diabetes (101).
Increased IMCL is postulated to cause defects in insulin signaling in muscles and liver,
reduce insulin stimulated muscle glucose transport activity and glycogen synthesis in
muscles, and impair insulin suppression of hepatic glucose production (37).
Magnetic resonance spectroscopy has recently been developed as a noninvasive
imaging method for assessing muscle lipid content and appears to be able to distinguish
between intramyocyte and extramyocyte lipid (17). IM TG is increased in obesity and is
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correlated with the severity of insulin resistance (102). A number of studies assessing
muscle attenuation characteristics on computed tomography imaging have also indicated
increased lipid content in association with obesity and type 2 DM and as a determinant of
insulin resistance (99,103-105).
Increases in IMTG have also been found in non-obese, first-degree relatives of
individuals with T2DM and was found to relate to insulin resistance in this population
(106). These data suggest that the regional deposition of fat within skeletal muscle may
be an early body composition abnormality in relation to insulin resistance, obesity, and
type 2 diabetes rather than arising only as a late complication of excess adiposity. The
fact that lipid accumulation can be seen relatively early in the development of insulin
resistance adds to the concept that perturbed lipid metabolism by skeletal muscle may
have a pivotal role in the development of obesity and type 2 DM (17).
Although the association between increased muscle TG and insulin resistance is
compelling, the mechanism is still not yet clear. It has been shown that endurance
athletes have high intramyocellular TG content despite the fact of being highly insulin
sensitive (107). It has also been known that short-term exercise training in humans
improves muscle insulin sensitivity without an accompanying measurable changes in
muscle TG content (108). In order to account for this apparent discrepancy, it has been
proposed that TG accumulation within the insulin resistant muscles is merely a marker
for some other harmful fatty acid metabolites, particularly diacyl glycerol (109),
ceramide (110), and long chain acyl CoA (111) are elevated in some insulin resistant
muscle models. The proposed mechanism of action for each of these metabolites is
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mediated through their negative effects on insulin signaling via activation of isoforms of
protein kinase C (109-114), and inhibition of activation of protein kinase B (115-117).
Liver triglceride and insulin resistance
Ectopic fat storage in the liver is also of pathphysiological importance. Studies
have shown that subjects with type 2 diabetes have significantly higher hepatic fat
content as compared to fat, sex and age matched non-diabetic subjects. Hepatic fat
content measured by nuclear magnetic resonance was also associated with insulin
resistance (35). Fat accumulation in the liver was reported to be also associated with
impaired insulin suppression of hepatic glucose production (118).
Examples of ectopic fat storage and insulin resistance
A. Lipodystrophy: This is a syndrome that is characterized by diabetes mellitus and
decrease in adipose tissue mass. Due to this insufficiency of adipose tissue mass, the
excess energy is stored as TG in the liver and skeletal muscle, followed by insulin
resistance and diabetes (119,120). Transgenic animals models that lack adipose tissue
development showed ectopic fat infiltration in the liver and skeletal muscles followed by
insulin resistance and diabetes (121-123). Interestingly, adipose tissue transplantation
back to these lipodystrophic animals reversed their hyperglycemia (124). These
experiments indicate that inadequate adipose tissue mass is as deleterious as excess fat,
and predisposes to insulin resistance and type 2 diabetes.
B. Obesity: Positive energy balance leads to metabolic disturbance that is similar to
lipodystrophy in humans. This effect is excess lipid storage in the liver, and skeletal
muscle (35-37), followed by glucose intolerance, insulin resistance and diabetes. The
difference here is that adipose tissue stores are adequate or even large in these obese
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patients, but is inadequate to sequester dietary lipid away from the liver, skeletal muscle,
and pancreas. This explanation is supported by studies using thiazolidinedione which
activates PPAR-γ, induced the differentiation of new fat cells in the subcutaneous adipose
tissue, and decreased lipid infiltration in the liver and skeletal muscles.

These

observations suggest that pharmacological therapies designed to target ectopic fat storage
may be used as a strategy to improve insulin resistance, and prevention and control of
diabetes (125,126).
8) The link between fatty acid oxidation and ectopic fat storage
An alternative explanation of the excess fat storage is that the whole-body fat
oxidation is impaired in obese subjects (16), leading to ectopic fat accumulation and
eventually insulin resistance. So it is hypothesized that the machinery for fatty acid
oxidation is insufficient to match the dietary fat load, or not properly activated in a timely
fashion by signals to oxidize fats. Another possibility is that the mitochondrial fatty acid
transporter availability is decreased.

McGarry and coworkers studies on rodents

indicated that inhibition of fatty acid oxidation increased intracellular lipids and
decreased insulin action in vivo, and there was a strong correlation between them (127).
Research on humans indicated that increased respiratory quotient (which is an indicative
of decreased post absorptive fat oxidation) predicts weight gain (128-130) and is
associated with deterioration of insulin sensitivity.
The control of fatty acid oxidation is the key for energy balance that regulates
other metabolic processes, such as lipolysis and lipogenesis (131). When the capacity to
oxidize fat is not properly activated by signals necessary to oxidize fat, or insufficient to
match the dietary fat intake, the excess fat accumulates in the ectopic fat storage. Muscle
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biopsies from patients with type 2 diabetes showed impaired mitochondrial capacity for
fatty acid oxidation (16,132). The defect in mitochondrial oxidative capacity was found
to be inherited since the lean offspring of type 2 diabetes patients proved to have the
same defect (133).
Fatty acid oxidation may be also regulated by neural-endocrine mechanism. The
use of synthetic beta-adrenergic agonists increased β-oxidation and improved insulin
sensitivity in healthy young men (134,135). It is possible that the sympathetic nervous
system (SNS) regulates fat oxidation, body weight, and insulin sensitivity. This was
based upon the finding that low SNS activity has been linked to wait gain and decreased
fat oxidation (136).
9) Pathogenesis of diabetic dyslipidemia
A significant component of the risk associated with type 2 diabetes is attributed to
the characteristic lipid triad profile of raised small dense low density lipoproteins
(sdLDL) levels, lowered high density lipoprotein (HDL), and elevated triglycerides (TG).
There is now an increased evidence of the major importance of diabetic dyslipidemia as a
cause of CVD rather than hyperglycemia (140).
Insulin resistance leads to impairment of the normal insulin mediated suppression
of FFA release from visceral adipose tissue. This in turn leads to increased flow of FFA
to the liver, which results in overproduction of very low-density lipoproteins (VLDL),
and increased plasma TGs. This is further exacerbated by the reductions in lipoprotein
lipase (LPL) activity and decreases in TG metabolism that are associated with insulin
resistant state. In turn the hypertriglyceridemia causes lowered HDL-C levels and
increased sdLDL (141).
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The major disposal route for hepatic fatty acids and TG are the export of hepatic
VLDL and the oxidation of fatty acids in the mitochondria, peroxisomes, and microsomes
(142,143). Genetic and environmental factors are important factors. Impaired fatty acid
β-oxidation capacity and defective VLDL transport system that impair lipid exporting
capacity result in accumulation of hepatic triglyceride, and fatty liver (144,145).
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ChapterⅢ: Experimental Section
1) Abstract
The TALLYHO/Jng (TH) mice are a newly established inbred polygenic model of type 2
diabetes and characterized by insulin resistance, hyperinsulinemia, hyperglycemia
(males),

obesity,

and

dyslipidemia.

Our

previous

study

demonstrated

that

hypertriglyceridemia is profoundly associated with insulin resistance and hyperglycemia
in male TH mice. Therefore, we hypothesize that abnormalities in lipid metabolism may
underlie the development of diabetes in male TH mice. In present study, we have
determined triglyceride levels and accumulation in non-adipose tissue including liver,
skeletal muscle, kidney, and pancreas of diabetic TH mice to assess the role of ectopic fat
in diabetes of TH model. Also, we have evaluated fatty acid oxidation in liver and
adipose tissue of TH mice in an attempt to understand the mechanism of
lipodysregulation in these mice. Compared to C57BL/6J (B6) as control, diabetic TH
mice exhibited significantly elevated triglyceride content in skeletal muscle and kidneys
that was effectively reduced by bezafibrate, an agonist of peroxisome proliferatorsactivated receptor-α, treatment. Hepatic 3H-palmitate oxidation rates were reduced in
diabetic TH mice compared to B6 controls, although this difference did not approach
statistical significance. Further, a marked accumulation of lipid droplets in liver was
exhibited in TH mice. In summary, the development of insulin resistance and diabetes in
TH mice may be associated with increased fat content of non-adipose tissue in these
mice. The elevation of tissue lipid possibly resulted from the hypertriglyceridemia that
may be in part caused by reduced hepatic β-oxidation in TH mice.
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2) Introduction
Type 2 Diabetes is one of the fastest growing public health problems in the
increasingly obese western society (33). By the year 2020, more than 250 million people
will be affected worldwide, resulting in a substantial financial burden, with more than
$100 billion spent annually in the United States alone (55,56,146). The relationship
between obesity and diabetes is of a such great interdependence that the term diabesity
has been applied (147). Ford et al., stated that for every kilogram weight gain, the risk of
diabetes increases between 4.5-9% (147).
Cross sectional studies have demonstrated the presence of insulin resistance in
virtually all patients with type 2 diabetes, and prospective studies have demonstrated the
presence of insulin resistance one to two decades prior to the onset of the disease (55-57).
Insulin resistance in the offspring of parents with type 2 diabetes has been shown to be
the best predictor for the later development of the disease (58), and perturbations that
reduce insulin resistance may prevent the development of diabetes (59). Therefore it is
important to understand the pathogenic mechanisms of insulin resistance in order to
identify novel targets for primary and secondary prevention (44). Alteration in lipid
metabolism and in free fatty acid supply as well as lipid induced attenuation of insulin
signaling received much less attention as a cause of diabetes (78). Indeed, both rodents
and human studies observed a correlation between the degree of insulin resistance in vivo
and the triacylglyceride (TG) content of non-adipose tissue including the skeletal muscle,
the primary target for insulin stimulated glucose disposal.
Further, biochemical analysis of human muscle biopsies (148,149) and in vivo
studies indicated that the obese, insulin resistance phenotype is associated with decreased
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fatty acid oxidation capacity in the mitochondria characterized by decreased number of
mitochondria, unusual mitochondrial morphology, decreased levels of mitochondrial
enzymes (including succinate dehydrogenase (107,150), citrate synthase and carnitine
palmitoyl transferase (132,151-153). It is therefore proposed that decreased fatty acid
oxidation capacity may exacerbate lipid accumulation particularly in the presence of
elevated plasma free fatty acid levels (154).
TALLYHO/Jng (TH) mice are a model for obesity and type 2 diabetes that are
characterized by insulin resistance, hyperinsulinemia, hyperglycemia (males), obesity,
and dyslipidemia associated with increased TG, free fatty acids (FFA) and cholesterol
levels. TH females are normally not diabetic, and this gender dimorphism for diabetes
seems to be commonly observed in mice (155-158).
In our previous study, it was observed that the plasma TG levels in TH male mice
were significantly associated with insulin resistance and diabetes and preceded the
development of diabetes in male TH mice.

Therefore we hypothesized that

lipodysregulation possibly caused by insulin resistance is responsible for the
hypertriglyceridemia (HTG) that might lead to ectopic fat accumulation and the
development of overt diabetes in TH male mice. To test this hypothesis in the present
study we have evaluated β-oxidation and ectopic fat accumulation in TH mice.
3) Materials and methods
Animals
All animals were allowed free access to food and water in a temperature and
humidity controlled room with 12:12- hours light-dark cycle. Mice were weaned onto
standard rodent chow [4% fat, Harlan Teklad Rodent diet (w) 8604, Harlan Teklad;
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Madison, WI]. All animal studies were carried out with the approval of the University of
Tennessee Animal Care and Use Committee.

Mice were euthanized by CO2

asphyxiation.
Tissue Triglyceride
Age and sex matched groups of TH and C57BL/6J (B6) mice were euthanized
with CO2.

Liver, kidney, muscles (soleus and gastrocnemius) and pancreas were

dissected and stored in – 80°C. Lipid extracts were prepared from the tissues using the
method of Hong Lan et al (159) and TG content was measured with an assay based on the
detection of glycerol (160). Briefly, tissues (10-13 mg) were minced in chloroform and
methanol (2:1 vol: vol) and incubated at –20° C overnight to release lipid before
centrifugation at 1,200 rpm for 10 minutes at 4° C. The supernatants (the organic phase)
were then collected and washed once with H2O. Lipids in the organic phase were
transferred into a new tube, dried, and re-dissolved in 200μl thesit solution (88317,
Sigma). TG content was measured using colorimetric kit (Sigma, TR0100).
Bezafibrate Effect on Tissue Triglyceride
At 6 week of age, mice were fed customized bezafibrate (1.5 gm/kg of diet,
Sigma) containing or regular chow diet for 17 weeks. At the end of the study mice were
killed and tissue TG content was measured as described above.
Histological examination
Age and sex matched TH and B6 mice were euthanized with CO2.

Tissue

samples from the liver and kidney were dissected, fixed in alcoholic formalin, cut into
2mm thick slices, washed well, and postfixed in 1% osmium tetoxide (OsO4). Paraffin
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sections, 4 microns thick, counter stained with nuclear fast red were examined under a
light microscope.
3

H-Palmitate oxidation in hepatocytes

A. Hepatocyte Isolation
Hepatocytes were isolated following the method of A.W. Harman et al (161) in
which the mice were anesthetized using tribromoethanol (Avertin 1.25%) (0.02 ml/gm
body weight is the does for B6 mice and 0.03 ml/gm-body weight for TH mice). A
longitudinal incision was made into the abdomen and chest cavity. Briefly, the liver was
perfused in a retrograde fashion with a modified Hank’s buffer (116 Mm NaCl, 5.4 Mm
KCL, 0.8 mM MgSO4, 3 mM Na2HPO3, 26mM NaHCO3, 20 mM Hepes), pH 7.3, and
37°C, containing 0.1 mM EGTA for 3 minutes. Perfusion was then continued for a
further 8 minutes with modified Hanks buffer containing 1 mM CaCl2, and collagenase
(0.4 mg /ml). Flow rates were controlled by a perfusion pump (Variable flow mini pump,
13-876-1 Fischer) at 4ml/minute. After perfusion, the liver was excised and gently teased
apart using a blunt spatula. The resulting cell suspension was filtered through two layers
of nylon mesh (250 and 100 μm) to remove undigested material. The cell suspension was
then centrifuged at 53 g for 2 minutes, and washed in the Hanks buffer containing 1 mM
CaCl2 for three times. The cells were then suspended into RPMI 1640 culture medium:
HYQ RPMI-1640 medium, Cell culture reagents with 25mM HEPES with L- glutamate
(SH 30255.01, Hyclone) containing 100U/ml penicillin, and 0.1 mg/ml streptomycin
(15070-063, GIBCO). Cell viability was tested using Trypan blue exclusion test using
0.4% trypan blue. Cells were counted using a hemocytometer.
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B. β- Oxidation of the liver
Freshly isolated hepatocytes were plated in a density of (10)5 cells/well in 24 well
culture plates. Plates were incubated 20 hours at 37°C in 5% CO2. Palmitate oxidation
was assayed using [9,10 3H] palmitate substrate (54 Ci/mmol) by the method of Moon
and Rhead (162)& Dolittle (163). Cell monolayers were rinsed twice with phosphate
buffer saline and incubated for 2 hours in 0.2 ml of substrate mixture containing 22 μm
unlabelled palmitate, 5 μci (3H) palmitate in Hanks buffer solution containing 0.5 mg/ml
BSA. The reaction medium was collected, and treated with 0.2 ml 10% trichloroacetic
acid. The cell monlayer was washed with additional 0.1 ml PBS and the wash was
pooled with the initial reaction medium, and centrifuged at 13.000 Rpm. Supernatants
were treated with 70 μl of 6 N NaOH, and applied to a 1 ml Dowex column. The 3H2O,
which is an end product of oxidation, passes through the column. This sample was
collected, together with 1 ml water wash to be directly quantitated as a measure of βoxidation, using a β- counter.
[3H] Palmitate oxidation in adipose tissue
Fresh fat pads were collected, cut into small pieces, and digested in KREBS
buffer containing 1% collagenase (collagenase type 1, 1700-017, GIBCO). The digest
was then filtered through gauze (600 μm) to remove debris. The adipocyte layer was
collected, washed, and diluted to a total volume of 2 ml in RMPI for 2 (1ml) duplicate
samples. Two hundred μl duplicate samples were collected in eppendorf tubes and stored
at –80°C DNA measurement. Duplicate samples of 1ml volume were incubated with 1
μci [9, 10-(N)-3H palmitate (P-1077, SIGMA) for one hour at 37°C in 5% CO2 incubator.
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After the addition of 1 ml trichloracetic acid, samples were extracted with 4 ml
chloroform and applied to 1 ml dowex column over a layer of glass wool in a Pasteur
pipette. Aliquots of the aqueous phase were collected in scintillation vials. Ten ml of
scintillation cocktail were added, and samples were counted using a Beta counter (164).
Protein assay for hepatocytes
Twenty four well Plates were frozen to –80°C and thawed to 37° C. Protein
content was determined by the modified Micro-Lowery method using a commercial kit
(TP0300, SIGMA) with bovine serum albumin as a standard (690-A, Sigma).
DNA assay
DNA content in adipocytes was measured using CyQUAVT cell proliferation
assay kit (C7026, Molecular Probes) was used. Cpm count was divided by DNA content.
Statistics
Statistical analysis for all the assays was conducted by ANOVA using Stat view
(Abacus Concepts; Berkeley, CA).

All data are presented as means ± SE.

4) Results
Tissue triglycerides
TH male mice exhibited significantly higher tissue TG levels in the kidney,
muscle, and soleus muscle compared to age- and sex-matched B6 mice. No statistically
significant differences were observed in liver and pancreas although increased trends
were seen in TH mice. In females, TH exhibited a significantly increased TG content in
pancreas compared to B6 females (all mice were 21 weeks old) (Figure 7).
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Figure 7: Tissue triglyceride content in 21 weeks old TALLYHO/Jng and C57BL/6J
male (A), and female mice (B). A statistically significant high triglyceride levels were
detected in the gastrocnemius (GC), soleus muscle (Sol.Ms), and kidney of TH males (n
= 5) compared to B6 males (n = 7) and in the pancreas of TH females (n = 7) compared
to B6 females (n = 6). * p = < 0.05 ** and p = < 0.01 vs. B6 in each tissue. B6 in each
tissue. Black and white bars represent B6 and TH respectively.
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Bezafibrate effect on tissue TG level
Bezafibrate treatments resulted in a significant reduction in tissue TG content in
the liver, muscle and soleus muscle in TH male mice to a level that is close to that in B6
mice. There was no significant bezafibrate effect on TG content in the kidney, likely due
to the large variation.
The effect of the bezafibrate containing diet on tissue TG levels in B6 mice in TH
females was not consistent, possibly because the basal tissue TG levels in these groups
were not elevated (Figure 8).
Histological examination
Microscopic examination revealed lipid accumulation throughout the hepatic
parynchema of male TH mice as indicated by OsO4 staining, but in B6 mice, lipid
accumulation was restricted to stellate cells (Ito) cells (Figure 9). In the kidney, proximal
cortical tubular epithelial cells in B6 mice contained small apical cytoplasmic lipid
droplets whereas larger accumulations were found in some renal epithelial cells of TH
mice (Figure 9).
β- Oxidation of 3H palmitate in hepatocytes
Although there was a trend that β-oxidation of TH male hepatocytes was lower
than that of age- and sex- matched B6 mice, the difference was not statistically
significant. Female TH mice also had a trend of lower β-oxidation, but the difference
was not statistically significant (Figure 10 A).
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Figure 8: Bezafibrate effect on tissue triglyceride content in 21 weeks old TH and B6
mice. Sex and age matched groups of mice were fed regular chow diet or customized
bezafibrate containing diet for 17 weeks. (A) TH males (n = 5 mice in each tissue), (B):
B6 males (n =7, regular chow; n = 3, bezafibrate diet), (C) TH females (n = 7, regular
chow; n = 4 mice, bezafibrate diet), and (D) B6 females (n = 7 mice, regular chow; n = 6
mice, bezafibrate diet). Black and white bars represent mice on regular chow diet and
bezafibrate containing diet, respectively.
* p <0.05 vs. chow diet in each tissue
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Figure 9: Osmium tetroxide staining of the liver and kidneys to detect lipid in 21
weeks old TH and B6 mice. In the liver, lipid was common in hepatocytes of TH mice
(A) but was restricted to hepatic stellate (Ito) cells (arrow) in B6 mice (B). In the kidney,
small lipid droplets were present in renal proximal convoluted tubules of B6 mice (arrow,
D) and larger deposits were scattered in tubular epithelial cells of TH mice
(Arrow, C). The scale bar indicates 50 μm.
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Figure 10: β-oxidation of 3H palmitate in hepatocytes (A) and
adipocytes (B) in 13 weeks old TH and B6 mice. Freshly isolated
hepatocytes and adiopocytes were incubated with 3H palmitate. The
release of 3H2O was quantitated as a measure for β-oxidation.
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β-oxidation of 3H palmitate in adipocytes
Although there was a slight trend that β-oxidation rates in TH male mice were
lower than age and sex matched B6 mice, the difference was not statistically significant
(Figure 10 B).
5) Discussion
In the present study, we have demonstrated that diabetic TH male mice exhibit
significantly elevated TG content and lipid accumulation in non-adipose tissue including
skeletal muscle, liver, and kidney. Further, bezafibrate, known as a plasma lipid lowering
agent, effectively reduces the tissue TG content in these mice. Attenuated hepatic fatty
acid oxidation was also featured in male TH mice although it was not statistically
significant.
Several human studies and animal studies using transgenic animal models with
alteration in the muscle TG content have demonstrated a positive correlation of
intramyocellular lipids (IMCL)-triglyceride content with insulin resistance. Conversely,
studies on animal models with diminished IMLC showed improved insulin sensitivity
(165,166).
Also, in human studies, intravenous lipid infusion increased IMCLs rapidly and
high fat feeding for 3 days increased IMCL content modestly (167), and weight loss
decreased IMLCs with concomitant improvement of insulin sensitivity (168). It has been
hypothesized that IMCL is caused by decreased capacity of fatty acid β-oxidation in
muscles (169) and the excess lipid stored is not mobilized, and may affect insulin
sensitivity by the production of lipid peroxidation products such as 4-HNE and /or
malondialdehyde (170).
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Shulman et al., have also demonstrated that high fat feeding caused hepatic fat
accumulation that is strongly associated with hepatic insulin resistance in the absence of
peripheral fat accumulation or peripheral insulin resistance in male Spargue-Dawley rats.
They speculated that fat induced hepatic insulin resistance might be due to activation of
PKC∈and/or JNK1, which might lead to impairment of IRS-1and IRS-2 tyrosine
phosphorylation. This block in insulin signaling limits the ability of insulin to activate
glycogen synthase. They also found that fat accumulation increased the contribution of
gluconeogenesis to total endogenous glucose production. Treatment of the high fat diet
fed rat with low dose 2,3 dinitrophenol to increase energy expenditure resulted in
prevention of hepatic fat accumulation and activation of PKC∈ and JNK 1. This in turn
preserved the insulin signaling and prevented the development of hepatic insulin
resistance(171). Therefore, it is speculated that the hypertriglyceridemia developed at
young age may then lead to accumulation of intramyocellular and hepatic lipids which
then contribute to the development of overt diabetes in male TH mice. Evaluation of
altered lipid accumulation in these cells of male TH mice at pre-diabetic stage remains to
be determined.
The pharmacological treatment with bezafibrate aimed at lowering plasma
triglyceride showed also improvement in tissue TG accumulation in male TH mice.
Whether this diminished tissue TG content may ameliorate insulin resistance and diabetes
in TH male mice, however, remains to be evaluated.
Acute increase in free fatty acids has a stimulatory effect on pancreatic β-cells
insulin secretion.

In contrast, chronic FFAs elevation results in reduced glucose
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stimulated insulin secretion. Prolonged in vitro exposure of β-cells to FFAs, TGs, or
glucose leads to stimulation of lipogenesis and /of increased fatty acid estrification and
intracellular fat deposition, which is associated with β-cell dysfunstion in animal studies.
A study on Zucker diabetic fatty rats indicated that abnormalities in insulin
secretion in these rats are attributed to a 50-fold increase in islet TG content compared to
normal control group.

Furthermore, incubation of the islets in triglitazone, which

simultaneously reduced islet TG content, resulted in improvement in insulin secretion.
Another possible mechanism for TG induced β-cell lipotoxicity is the increased
formation of nitric oxide which induced β-cell apoptosis(172-174).
In our study, pancreatic TG content was found to be elevated in TH mice
compared to age and sex matched B6 mice, which might be a contributing factor in the
development of insulin resistance and type 2 diabetes in these mice. Although TH
females are not normally hyperglycemic (176) they had a significantly higher pancreatic
TG content compared to age matched B6 females that still needs to be explained.
Protection from diabetes in females has known to be attributed to low hepatic estrogen
sulfotransferase activity in female mice (177). Sex dimorphism for diabetes appears to be
commonly observed in mice (178-180).
Plasma levels of TG are largely controlled by TG synthesis and secretion from the
liver in a cooperative manner with lipolytic activity in adipose tissue; for example,
promotion of TG hydrolysis in adipose tissue by lowering insulin (i.e. through fasting) or
by insulin resistance (to lowering lipolysis) increases plasma FFA that are then taken up
by the liver and either re-esterifed to TG and secreted as TG-rich lipoprotein, very low
density lipoproteins (VLDL), or oxidized (181). It is, therefore, plausible to speculate
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that chronic inhibition of fatty acid oxidation in the liver might cause an increase in reesterification of fatty acid uptaken to TG as a default, which in turn increases TG
secretion as VLDL form as well as tissue accumulation in male TH mice. Investigating
whether impaired β-oxidation is also attributable to the excess lipid accumulation in the
skeletal muscle of male TH mice will further elucidate the link between lipodysregulation
and insulin resistance in TH model and remains to be conducted.

Interestingly,

stimulation of β-oxidation by over-expression of CPT 1 significantly improved insulin
response in L6 myocytes (154).
In summary, an excess lipid accumulation in non-adipose tissue becomes apparent
in hypertriglyceridemic and diabetic TH male mice. It is likely that impaired fatty acid
oxidation in liver may be in part responsible for the hypertriglyceridemia, leading to TG
accumulation in peripheral tissue including the skeletal muscle in TH mice.

This

increased non-adipose triglyceride levels may be attributable to the impaired insulin
sensitivity and diabetes in these mice.

44

Conclusions and Future Directions:
Our studies demonstrated a significant association between lipodysregulation and type 2
diabetes in TH mice. Further experimentation on TH mice tissue TG content at an earlier
stage (younger age) before the onset of diabetes is required. Examining the effect of
bezafibrate on β-oxidation, and whether it improves or prevents insulin resistance and
hyperglycemia in TH mice, will be also valuable.
One notable finding from the present study is a drastic elevation of TG content in
soleus muscle in TH male mice. The role of intramyocellular lipids content in mediating
insulin resistance has been well demonstrated in humans and animal models. Therefore,
our long-term goals include studying intramyocellular lipid deposits and the related
insulin sensitivity and signaling in TH mice.

This study will also be extended to

investigation of mechanisms including fatty acid uptake and lipid oxidation in skeletal
muscle.
Despite the enormous research work done to explore the pathogenesis of diabetes,
the question of what causes type 2 diabetes might be one of the most frequently asked
and least satisfactorily answered in the history of diabetes research. Elucidating the
mechanism of lipodysregulation in diabetic model of TH mice will provide insights into
the causes and mechanisms underlying the metabolic complications of insulin resistance
and diabetes. This will ultimately lead to improved therapeutic strategies for prevention
and treatment of type 2 diabetes.
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Table 1 A: Body mass index (BMI)
< 18.5

Underweight

18.5 – 24.9

Normal weight

25 – 29.9

Overweight (pre-obesity)

30-34.9

Grade 1 obesity

35– 39.9

Grade 2 obesity

> 40

Grade 3 obesity (Morbid Obesity)
Body mass index is calculated by dividing the weight
in kilograms (kg) by the height in square meters (m)2.

Tissue triglyceride measurement
1) Mice are euthanized with CO2.
2) Liver, kidney, muscles (soleus and gastrocnemius) and pancreas are dissected and
stored in – 80°C.
3) Lipid extracts were prepared from the tissues using the method of Hong Lan et al
(159):
•

Tissues (10-13 mg) are minced in 3 ml chloroform and methanol (2:1 vol: vol).
Use falcon blue cap tubes (Falcon, 352097).

•

Incubate at –20° C overnight to release lipids.

•

Centrifuge at 1,200 rpm for 10 minutes at 4° C.

•

Collect the supernatants (the organic phase) and wash once with H2O.

•

Centrifuge at 1,200 rpm for 10 minutes at 4° C.
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•

Transfer Lipids in the organic phase into a new Falcon tube.

•

Leave the tubes to dry under the hood. It takes up to 5 days to have the tubes
completely dried.

•

Re-dissolve the lipids in 200μl thesit solution (88317, Sigma).

•

Measure TG content using colorimetric kit (Sigma, TR0100).

Osmium Tetroxide procedure for fat staining
Fixative:
Alcoholic formalin.
Reagents:
Osmium tetroxide (4% aqueous solution, 20816-12-0, Electron Microscopy sciences).
Prepare 1% solution by dissolving osmium in 0.1 M Cacodylate Buffer. Store in a dark
container (or wrap with foil) in the refrigerator. The vapor is harmful, so prepare and use
the reagent under a fume hood.
Periodic acid solution 0.05% (S186-3202).
Procedure:
1) Trim buffered formalin-fixed tissue to 2mm thick and wash in running tap water for at
least 30 minutes. It is important to cut the tissue thin as osmium has a very low
penetrating power.
2) Rinse the tissue well in distilled water.
3) Place the tissue in 5 ml of osmium tetroxide 1% solution. Cap the container and leave
for 1-2 hours. Periodically agitate the solution containing the tissue.
4) Rinse tissue in two changes of distilled water for 15 minutes each.
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5) Differentiate by placing tissue in 10 ml of 0.5% periodic acid solution for 30 minutes.
Agitate the solution periodically. The background tissue will clear and leave the fat
stained black.
6) Wash the tissue in tap water for 30 minutes.
7) Place the tissue in a processing cassette (Omnisette tissue cassettes, Histoprep, Fischer
scientific) with the darker stained side facing down.
8) Cover the cassette completely with 70% alcohol, and send to the histopatholgy lab for
preparing paraffin sections and slides.
Hepatocyte isolation
Solutions:
1) Modified Hank’s buffer containing EGTA:
116mM NaCl.
5.4 mM KCl
0.8mM MgSo4 .7H2O
0.4 mM KH2PO4
0.3 mMNa2HPO3
26 mM NaHCO3
20 mM Hepes,
0.1mM EGTA. Bring to PH 7.3, 37° C.
2) Modified Hanks buffer containing 1 mM CaCl2 and collagenase 0.2 mg/ml ( with no
EGTA)
3) Modified Hanks buffer containing 1 mM CaCl2 without collagenase for wash.
Procedure for hepatocyte isolation:
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1) Oxygenate all the solutions and bring the temperature to 37°C using a water bath.
2) Anaesthetize the mouse with intraperitoneal injection of Avertin (1.25%). The dose is
0.02/mg for B6 mice, and 0.03 /mg for TH mice.
3) After the mouse is anaesthesized, lay it down on the back on a cork dissecting board
(NC 9063641, Fischer scientific). Fix the limbs with 4 pins.
4) Make a longitudinal incision in the abdomen and chest cavity.
Occlude the vena cava with an artery clamp (John Hopkins Bulldog clam, 1½ inches
straight, 34-2920, biomedical research instruments) in a position cranial to the hepatic
vein.
5) Insert an IV catheter (EXE safe left catheter, 24G X 3/4″, 14-841-21) into the
abdominal vena cava, caudal to the hepatic vein.
6) The portal vein is then severed using a superfine sissors (11-1020, 31/4 straight, needle
points, 0.2mm X 0.2 mm, Biomedical research Instruments). The liver is perfused in a
retrograde fashion with a modified Hank’s buffer containing EGTA , for 3 minutes .
Perfusion is then continued for a further 8 minutes with modified Hanks buffer
containing 1 mM CaCl2 and collagenase 0.2 mg/ml. Flow rates have to be adjusted at
4ml/minute. Flow is controlled by a perfusion pump (Variable flow mini pump, 13-8761 Fischer).
7) After perfusion, the liver is excised and gently teased apart using a blunt spatula.
Filter the resulting cell suspension through two layers of Nylon mesh (250 and 100 um)
to remove undigested materials.
8) Centrifuge the cell suspension at 53 g for 2 minutes.
9) Take the cell pellet, and re-suspend it in Hank’s buffer (containing 1 mM CaCl2).
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10) Repeat the centrifuge and washing for 3 times.
11) The cells are suspended into RPMI 1640 culture medium (HYQ RPMI-1640 medium.
Cell culture reagents with 25 mM HEPES with L- glutamate, SH 30255.01)
containing100U/ml penicillin, 1 mg/ml streptomycin.
12) Cell viability testing: Use Trypan Blue exclusion test.
13) Cell counting: Use a hemocytometer.
Reference: Isolation of hepatocytes from postnatal mice, Andrew W. Harman. 1986.
Assessment of Cell viability with Trypan Blue
Trypan blue is enables easy identification of dead cells. Dead cells take up the dye and
appear blue. In contrast, living cells repel the dye and appear refractile and colorless.
Procedure:
1) Prepare the hemocytometer for use by cleaning all surfaces and cover slip.
Completely dry using non-linting tissue (or air dry).

Center the cover slip on the

hemocytometer.
2) Transfer 50 μl of Trypan blue (0.4% solution in phosphate, 1691049) into a clean
eppendof tube.
3) Add 50 μl of the cell suspension in the tube containing the stain.
4) Mix the solution thoroughly, but gently. Cut the tips of the pipette to avoid cell
damage if narrow tips are used.
5) Allow the mixture to set for 2-3 minutes after mixing. Do not let the cells sit in the dye
for more than 5 minutes because both the living and dead cells will take up the dye after 5
minutes.
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6) Pipette 9 μl of the Trypan blue cell suspension mixture into one of the two containing
chambers. Fill the chamber slowly and steadily. Avoid injecting bubbles into the
chamber.
7) If > 60% of cells are viable, count the cells using a hemocytometer.
Procedure for cell counting:
1) Pipette 9 μl of the cell suspension in one of the two counting chambers as above.
Allow the suspension to settle for 10 seconds.
2) Count the cells in each of the four 1mm3 corner squares of the hemocytometer. Do
count the cells touching the top or left borders. Do not count the cells touching the
bottom or right borders.
Determine the cell count:
1) Calculate the total cells counted in the four corner squares.
2) If the total cell count is less than 100, or if more than 10% of cells counted appear to
be clustered, carefully remix the original cell suspension and repeat the counting.
3) If the total cell count is greater than 400, dilute the suspension, and repeat the
counting.
4) Calculate the cell count using the equation: cell/ ml =(n) x104
n = the average cell count per square of the four corner squares counted
5) Determine the total number of cells in the total suspension volume:
Determine the total volume of the cell suspension.
Multiply the volume of the cell suspension by the “cells/ml” value calculated above.
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β- oxidation of the liver:
Freshly isolated hepatocytes were plated in a density of (10)5 cells/well in 24 well culture
plates (multiwell, 24 wells, 353047, Falcon). Plates were incubated 20 hours at 37 °C in
5% CO2.

Palmitate oxidation was assayed using [9,10 3H] palmitate substrate (54

Ci/mmol) by the method of Moon and Rhead. The release of 3H2O was quantitated as a
measure of the rate of β-oxidation.
1) Cell monolayers are washed twice PBS.
2) Bring to a final concentration of 22 μM 3H palmitate and BSA (0.5mg/ml)(Bovine
serum albumin, A8022-50G) with Hanks buffered saline solution (HBSS X1, 14175-095,
GIBCO, Grand Island,N.Y.).
Reaction medium:
For each sample, triplicates of both sample and negative controls are needed. So each
sample will require 6 wells. Total reaction medium is 200 μl . (For 6 wells 200x6) +
additional 200ul.ie 1400 ul
Take 2 ml Hanks& add 1mg BSA (0.5 mg BSA/1ml Hanks).
Take 1400 ul and add 14 μl of unlabelled palmitate.
Add the radiolabel led palmitate (5.9 μl /well)i.e. 40.6 μl for 7 wells.
1) Apply 200 μl of this mixture to wells containing monolayer.
2) Cells are incubated in the above reaction mixture for 2 hours at 37°C in humidified 5%
CO2 in 95% air.
3) The reaction mixture is removed and added to an eppendorf tube containing 200 μl of
10% wt/volume trichloroacetic acid.
4) Each well is rinsed with 100 μl PBS which is added to the tubes.
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5) After 2 minutes at room temperature, the reaction mixture is centrifuged at 13.000
RPM in a Beckman centrifuge tube for 5 minutes.
6) Remove the supernatants immediately, and then add 6 N of NaOH (70 μl).
7) Apply to a 1 ml Dowex-1 column (Dowex 1x2 Cl- form strongly basic, 44290, Sigma
Aldrich) in a Pasteur pipette lined with a bottom layer of glass wool (P13-019-2).
8) Columns are rinsed with 1 ml of distilled water.
9) The eluate is collected in a scintillation vial containing 10 ml of scintiverse. The
samples are counted using a Beckman β-counter.
10) Add 0.5 ml H2O to each well and keep in -80°C. In order to determine protein
content, freeze and thaw ( -80°C and 37°C three times)before measuring protein content.
11) The protein content is determined using total protein kit, Micro Lowry, Peterson’s
modification, Tp0300, Sigma Aldrich, St. Louis, MO). Readings are measured
fluorometrically ( Spectrophotometer 336009-86, Spectrosonic GENESYS).
β- oxidation in adipose tissue:
1) Reconstitute KREBS buffer. Prepare 1% BSA solution by dissolving 1 gm of
BSA in 100 ml of KREBS buffer.
2) Prepare 1% collagenase (collagenase type 1, 1700-017, GIBCO) solution
(depending on the number of samples ex, for each sample you will need 4 ml of
1% collagenase. So take 4 ml of solution in step 1 in which you dissolve 40 mg
collagenase type 1).
3) Dissect the mouse and get the fat pads. Mince into little pieces and add to the 50
ml orange cap tube containing 4 ml of 1% collagenase.
74

4) Incubate in 37°C water bath for 40-60 minutes.
5) The digest was then filtered through gauze (600 μm) to remove debris. Stand for
10 minutes so that the fat cell layer floats.
6) Aspirate the lower phase using a glass Pasteur pippete, leaving the fat cell layer in
the tube.
7) Add 10 ml of 1% BSA KREBS buffer without collagenase and swirl gently.
8) Stand for 10 minutes and aspirate the lower phase as in step 6. Repeat the wash
twice.
9) Add 2 ml of KREBS buffer without collagenase of BSA. Swirl gently.
Take 200 Two hundred μl duplicate samples were collected in eppendorf tubes
and stored at –80°C DNA measurement.ul in eppendorf tube and keep in – 80°C
for DNA assay.
10) Aspirate the lower phase leaving the adipose tissue layer in the tube.
11) Add 2 ml RMPI containing 10% FBS and divide into 2 tubes to perform a
duplicate sample experiment. Duplicate samples of 1ml volume are incubated
with 1 μci [9,10-(N)-3H palmitate (P-1077, SIGMA) for one hour at 37°C in 5%
CO2 incubator. Leave the caps loose during incubation.
12) Add I ml trichloacetic acid to each tube.
13) Add 4 ml chloroform to each tube.
14) Take the upper phase (aquous phase).
15) Apply to 1 ml dowex column over a layer of glass wool in a Pasteur pipette.
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16) Aliquots of the aqueous phase were collected in scintillation vials. Ten ml of
scintillation cocktail were added, and samples were counted using a Beta counter
(164).
17) DNA assay is then performed . Cpm is divided by DNA content for each sample.
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